The use of a promising Caspase-1 inhibitor VX-765 was shown to reduce α-synuclein aggregation in transgenic mice multiple system atrophy (MSA) model and reduce neuroinflammation in Alzheimer mice model (Bassil et al., 2016; Flores et al., 2020). This evidence concerns the gene CASP1 and multiple system atrophy.